PsoriaVa™ (Calcipotriene/Betamethasone and DDAIP for the treatment of Psoriasis; Pre-IND)

Long term safety and efficacy continues to be elusive with psoriasis treatments. In a pre-clinical efficacy study, PsoriaVa™ delivered the same level of drugs as Taclonex^® (Calcipotriene 0.005%/Betamethasone 0.64%). In a second efficacy study, using the DNFB induced allergic contact dermatitis (ACD) pig model, results showed that PsoriaVa™ significantly lowered clinical inflammation and erythema scores in sick animals potentially achieving similar efficacy with superior safety to currently available therapies.

• 

  Worldwide rights available for partnering